Building upon the encouraging data with a quizartinib-based doublet, a subsequent study randomized older adults with newly diagnosed AML (irrespective of FLT3 mutation status) to LDAC with or without quizartinib [43]. Here, FLT3 is linked to acute myeloid leukemia.